Post-transplant lymphoproliferative disorder in adult liver transplant recipients: A South American multicenter experience

Clinical Transplantation

Volumn 27, Issue 4, 2013, Pages

  Mendizabal, Manuel ^a   Marciano, Sebastián ^b   dos Santos Schraiber, Luciana ^c   Zapata, Rodrigo ^d   Quiros, Rodolfo ^a   Zanotelli, Maria Lucia ^e   Rivas, María Marta ^a   Kusminsky, Gustavo ^a   Humeres, Roberto ^d   Alves de Mattos, Angelo ^c   Gadano, Adrián ^b   Silva, Marcelo O ^a  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b HOSPITAL ITALIANO DE BUENOS AIRES   (Argentina)

^c UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^d UNIVERSIDAD DEL DESARROLLO   (Chile)

^e Santa Casa de Porto Alegre   (Brazil)

Author keywords

Immunosuppression; Liver transplantation; Post transplant complications; Post transplant lymphoproliferative disorder

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE; RITUXIMAB;

ADULT; ARGENTINA; ARTICLE; BRAZIL; CHEMOTHERAPY; CHILE; FEMALE; HEALTH SURVEY; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POST TREATMENT SURVIVAL; POSTOPERATIVE COMPLICATION; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; SURGICAL MORTALITY; SURGICAL RISK;

IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; POST-TRANSPLANT COMPLICATIONS; POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDER;

ADULT; AGED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FAILURE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS; SOUTH AMERICA; SURVIVAL RATE; TIME FACTORS; YOUNG ADULT;

EID: 84881541625     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12152     Document Type: Article

References (36)

1. Penn I. Cancers complicating organ transplantation. N Engl J Med 1990: 323: 1767.
2. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2003: 4: 220.
3. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med 2005: 56: 29.
4. Leblond V, Sutton L, Dorent R et al. Lymphoproliferative disorders after organ transplantation: a report of 24 cases observed in a single center. J Clin Oncol 1995: 13: 961.
5. Jain A, Nalesnik M, Reyes J et al. Posttransplant lymphoproliferative disorders in liver transplantation: a 20-year experience. Ann Surg 2002: 236: 429; discussion 436-7.
6. Patel H, Vogl DT, Aqui NA et al. Posttransplant lymphoproliferative disorder in adult liver transplant recipients: a report of seventeen cases. Leuk Lymphoma 2007: 48: 885.
7. Koch DG, Christiansen L, Lazarchick J, Stuart R, Willner IR, Reuben A. Posttransplantation lymphoproliferative disorder-the great mimic in liver transplantation: appraisal of the clinicopathologic spectrum and the role of Epstein-Barr virus. Liver Transpl 2007: 13: 904.
8. Kremers WK, Devarbhavi HC, Wiesner RH, Krom RAF, Macon WR, Habermann TM. Post-transplant lymphoproliferative disorders following liver transplantation: incidence, risk factors and survival. Am J Transplant 2006: 6: 1017.
9. Lim WH, Russ GR, Coates PTH. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation. Nephrology (Carlton) 2006: 11: 355.
10. Cockfield SM. Identifying the patient at risk for post-transplant lymphoproliferative disorder. Transpl Infect Dis 2001: 3: 70.
11. Walker RC, Marshall WF, Strickler JG et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis 1995: 20: 1346.
12. Shpilberg O, Wilson J, Whiteside TL, Herberman RB. Pre-transplant immunological profile and risk factor analysis of post-transplant lymphoproliferative disease development: the results of a nested matched case-control study. The University of Pittsburgh PTLD Study Group. Leuk Lymphoma 1999: 36: 109.
13. Hézode C, Duvoux C, Germanidis G et al. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation. Hepatology (Baltimore, MD) 1999: 30: 775.
14. McLaughlin K. Increased risk for posttransplant lymphoproliferative disease in recipients of liver transplants with hepatitis C. Liver Transpl 2000: 6: 570.
15. Lee J-J, Lam MSH, Rosenberg A. Role of chemotherapy and rituximab for treatment of posttransplant lymphoproliferative disorder in solid organ transplantation. Ann Pharmacother 2007: 41: 1648.
16. Elstrom RL, Andreadis C, Aqui NA et al. Treatment of PTLD with rituximab or chemotherapy. Am J Transplant 2006: 6: 569.
17. Oertel SHK, Verschuuren E, Reinke P et al. Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD). Am J Transplant 2005: 5: 2901.
18. Smets F, Sokal EM. Epstein-Barr virus-related lymphoproliferation in children after liver transplant: role of immunity, diagnosis, and management. Pediatr Transplant 2002: 6: 280.
19. Tsai DE, Douglas L, Andreadis C et al. EBV PCR in the diagnosis and monitoring of posttransplant lymphoproliferative disorder: results of a two-arm prospective trial. Am J Transplant 2008: 8: 1016.
20. Baldanti F, Grossi P, Furione M et al. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders. J Clin Microbiol 2000: 38: 613.
21. Lee TC, Savoldo B, Rooney CM et al. Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipients. Am J Transplant 2005: 5: 2222.
22. Heslop HE. How I treat EBV lymphoproliferation. Blood 2009: 114: 4002.
23. Fanaian NK, Cohen C, Waldrop S, Wang J, Shehata BM. Epstein-Barr virus (EBV)-encoded RNA: automated in-situ hybridization (ISH) compared with manual ISH and immunohistochemistry for detection of EBV in pediatric lymphoproliferative disorders. Pediatr Dev Pathol 2009: 12: 195.
24. Preiksaitis JK, Diaz-Mitoma F, Mirzayans F, Roberts S, Tyrrell DL. Quantitative oropharyngeal Epstein-Barr virus shedding in renal and cardiac transplant recipients: relationship to immunosuppressive therapy, serologic responses, and the risk of posttransplant lymphoproliferative disorder. J Infect Dis 1992: 166: 986.
25. Bianco E, Marcucci F, Mele A et al. Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. Haematologica 2004: 89: 70.
26. Libra M, Gasparotto D, Gloghini A, Navolanic PM, De Re V, Carbone A. Hepatitis C virus (HCV) I hepatitis C virus (HCV) infection and lymphoproliferative disorders. Front Biosci 2005: 10: 2460.
27. Zein NN. Hepatitis C virus and lymphoproliferative disorders after liver transplantation. Hepatology (Baltimore, MD) 2000: 31: 808.
28. Morton LM, Landgren O, Chatterjee N et al. Hepatitis C virus infection and risk of posttransplantation lymphoproliferative disorder among solid organ transplant recipients. Blood 2007: 110: 4599.
29. Pirsch JD. Cytomegalovirus infection and posttransplant lymphoproliferative disease in renal transplant recipients: results of the U.S. multicenter FK506 Kidney Transplant Study Group. Transplantation 1999: 68: 1203.
30. Wiesner RH, Demetris AJ, Belle SH et al. Acute hepatic allograft rejection: incidence, risk factors, and impact on outcome. Hepatology (Baltimore, MD) 1998: 28: 638.
31. Rowe IA, Webb K, Gunson BK, Mehta N, Haque S, Neuberger J. The impact of disease recurrence on graft survival following liver transplantation: a single centre experience. Transplant Int 2008: 21: 459.
32. Tsai DE, Hardy CL, Tomaszewski JE et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001: 71: 1076.
33. Ghobrial IM. Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders. J Clin Oncol 2005: 23: 7574.
34. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993: 329: 987.
35. Ghobrial IM, Habermann TM, Macon WR et al. Differences between early and late posttransplant lymphoproliferative disorders in solid organ transplant patients: are they two different diseases? Transplantation 2005: 79: 244.
36. Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity? J Clin Oncol 1998: 16: 2052.